Artificial Tears Companies

Recall Updates In February 2023, the FDA issued a recall for EzriCare Artificial Tears and Delsam Pharma's Artificial Eye Ointment due to potential bacterial contamination. This incident highlighted the importance of manufacturing quality and safety in the artificial tears market.

Allergan (US) Launched Refresh® Bio, a new line of preservative-free and biocompatible artificial tears in July 2023, catering to users with sensitive eyes or preservative allergies.

Bausch + Lomb (US) Announced plans to expand its line of Systane® Complete artificial tears with new formulations addressing specific dry eye symptoms, offering targeted relief options for patients.

Johnson & Johnson (US) Received FDA approval for its Acuvue® Oasys with TearRelief Technology contact lenses in September 2023, which integrate a moisturizing agent within the lens for enhanced comfort and dryness relief.

Thea Laboratories (France) Collaborated with AI startup TearLab Corp. (US) to develop AI-powered diagnostic tools for personalized dry eye management, aiming to tailor treatment plans based on individual tear film analysis.

• Johnson and Johnson Vision Care (US)


• Allergan plc (Ireland)


• Alcon Plc (Switzerland)


• Bausch & Lomb Incorporated (Canada)


• Santen, Inc (Japan)


• URSAPHARM Arzneimittel GmbH (Germany)


• ROHTO Pharmaceutical CO., LTD (Japan)


• Similasan Corporation (US)


• Ocusoft (US)


• Nicox (France)